Study of JCXH-213 for adults with immune thrombocytopenia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an experimental medicine called JCXH-213 for adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. The study aims to see if this new treatment can help people who have not responded well to other ITP therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have had ITP for at least 3 months.
- You have already tried a corticosteroid (like prednisone) and it didn't work, or you stopped responding to it.
- You have also tried at least one other ITP treatment (like rituximab, eltrombopag, romiplostim, or similar) and it didn't work or you couldn't tolerate it.
- Your platelet count is low (below 30) before the study starts.
- You are generally well enough for daily activities (ECOG 0-2).
- You can take some stable ITP medicines during the trial if you've been on the same dose for at least 4 weeks.
- Your liver, kidney, heart, and blood counts meet certain safety levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine for children with a condition called immune thrombocytopenia (ITP), which causes low blood platelets and easy bruising or bleeding. It may help increase platelet counts when standard treatments haven't worked.
This study tests a new medication called SHR-2173 for people with immune thrombocytopenia (ITP) whose platelet count is low and who have already tried steroids without success. The goal is to see if this drug can help raise platelet counts and reduce bleeding risk.
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
This trial tests an experimental oral medication called TQB3473 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets causing low counts and bleeding risk. The goal is to see if the drug can safely improve platelet counts and reduce bleeding symptoms.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
Hear when a new Thrombocytopenic Purpura, Immune trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.